New research suggests that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional lifestyle regimens.
Research printed in a prominent medical journal demonstrates that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"People buying such medications need to be cognizant of the danger of rapid weight regain when the medication concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team note that people who shed pounds through lifestyle changes alone usually have a less rapid creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Regain
Experts suggest the mechanism of the drugs is key to understanding the accelerated regain.
The injections mimic a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the therapy might need to be long-term.
This view is supported by pharmaceutical companies, who note that the findings "underscore the chronic nature of excess weight," similar to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the jabs report a powerful return of appetite.
"I experienced a switch flipping and I was suddenly starving," recalled one woman.
This difficulty is worsened if individuals have not established sustainable lifestyle or habit modifications during therapy.
Widespread Interest
Figures suggest that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Use is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, researchers caution that while the jabs are effective tools for weight loss, they are not a magic fix and lasting health benefits relies on integrated behavioural support.